Covered recipient · General Payments record
SHELLEY ROSE PERRY
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner
General Payments · PY2021–2024
$1,683.96
- Reported across 92 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $383.40 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $103.28 | 3 |
| Grifols USA, LLC | $64.91 | 3 |
| DEXCOM, INC. | $54.83 | 1 |
| ABBVIE INC. | $39.41 | 2 |
| PFIZER INC. | $28.16 | 1 |
| Otsuka America Pharmaceutical, Inc. | $24.26 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $23.45 | 1 |
| Novo Nordisk AS | $16.07 | 1 |
| Merck Sharp & Dohme Corporation | $15.72 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $13.31 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $19.06 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107838140 | CMS |
| ABBVIE INC. | $20.35 | 04/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107838142 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $13.31 | 09/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086325150 | CMS |
| Dexcom, Inc. | $54.83 | 06/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153386812 | CMS |
| Grifols USA, LLC | $17.68 | 06/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124715949 | CMS |
| Grifols USA, LLC | $23.95 | 07/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124715951 | CMS |
| Grifols USA, LLC | $23.28 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124715953 | CMS |
| Lilly USA, LLC | $13.99 | 01/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135948223 | CMS |
| Lilly USA, LLC | $19.43 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135909213 | CMS |
| Lilly USA, LLC | $69.86 | 07/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135953199 | CMS |
| Merck Sharp & Dohme LLC | $15.72 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141806527 | CMS |
| Novartis Pharmaceuticals Corporation | $23.45 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087229915 | CMS |
| Novo Nordisk Inc | $16.07 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100477672 | CMS |
| Otsuka America Pharmaceutical, Inc. | $24.26 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119161747 | CMS |
| PFIZER INC. | $28.16 | 07/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131682730 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.